Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.
Eli Lilly And Co (NYSE:LLY) announced the results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet). Emgality did not meet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results